McConkey B, Amos R S, Butler E P, Crockson R A, Crockson A P, Walsh L
Agents Actions. 1978 Jun;8(4):438-41. doi: 10.1007/BF01968673.
After a 12-week preliminary period of observation 32 patients with consistently active rheumatoid arthritis (RA) were treated for up to 22 weeks with salazopyrin. Seven patients could not tolerate the drug. The remaining 25 patients had a marked improvement in subjective clinical state and significant falls in serum C-reactive protein and the erythrocyte sedimentation rate 6 weeks after treatment began. The improvement was maintained after 22 weeks. The results strongly suggest that further trials with this drug in RA are needed.
经过12周的初步观察期后，32例类风湿性关节炎（RA）持续活动的患者接受了柳氮磺胺吡啶治疗，疗程长达22周。7例患者无法耐受该药物。其余25例患者在治疗开始6周后主观临床状态有明显改善，血清C反应蛋白和红细胞沉降率显著下降。22周后改善情况得以维持。结果强烈表明，需要对该药物在类风湿性关节炎中的应用进行进一步试验。
